Tags

Type your tag names separated by a space and hit enter

Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer.
Gastroenterology 2008; 134(1):95-101G

Abstract

BACKGROUND & AIMS

The temporal association between diabetes mellitus and pancreatic cancer is poorly understood. We compared temporal patterns in diabetes prevalence in pancreatic cancer and controls.

METHODS

We reviewed the medical records of pancreatic cancer cases residing within 120 miles or less of Rochester, Minnesota, seen at the Mayo Clinic between January 15, 1981, and July 9, 2004, and approximately 2 matched controls/case residing locally. We abstracted all outpatient fasting blood glucose (FBG) levels for up to 60 months before index (ie, date of cancer diagnosis for cases) and grouped them into 12-month intervals; 736 cases and 1875 controls had 1 or more outpatient FBG levels in the medical record. Diabetes was defined as any FBG level of 126 mg/dL or greater or treatment for diabetes, and was defined as new onset when criteria for diabetes were first met 24 or fewer months before index, with at least 1 prior FBG level less than 126 mg/dL.

RESULTS

A higher proportion of pancreatic cancer cases compared with controls met the criteria for diabetes at any time in the 60 months before index (40.2% vs 19.2%, P < .0001). The proportions were similar in the -60 to -48 (P = .76) and -48 to -36 (P = .06) month time periods; however, a greater proportion of cases than controls met criteria for diabetes in the -36 to -24 (P = .04), -24 to -12 (P < .001), and -12 to 0 (P < .001) month time periods. Diabetes was more often new onset in cases vs controls (52.3% vs 23.6%, P < .0001).

CONCLUSIONS

Diabetes has a high (40%) prevalence in pancreatic cancer and frequently is new onset. Identification of a specific biomarker for pancreatic cancer-induced diabetes may allow screening for pancreatic cancer in new-onset diabetes.

Authors+Show Affiliations

Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. chari.suresh@mayo.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18061176

Citation

Chari, Suresh T., et al. "Pancreatic Cancer-associated Diabetes Mellitus: Prevalence and Temporal Association With Diagnosis of Cancer." Gastroenterology, vol. 134, no. 1, 2008, pp. 95-101.
Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134(1):95-101.
Chari, S. T., Leibson, C. L., Rabe, K. G., Timmons, L. J., Ransom, J., de Andrade, M., & Petersen, G. M. (2008). Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology, 134(1), pp. 95-101.
Chari ST, et al. Pancreatic Cancer-associated Diabetes Mellitus: Prevalence and Temporal Association With Diagnosis of Cancer. Gastroenterology. 2008;134(1):95-101. PubMed PMID: 18061176.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. AU - Chari,Suresh T, AU - Leibson,Cynthia L, AU - Rabe,Kari G, AU - Timmons,Lawrence J, AU - Ransom,Jeanine, AU - de Andrade,Mariza, AU - Petersen,Gloria M, Y1 - 2007/10/26/ PY - 2007/07/24/received PY - 2007/10/11/accepted PY - 2007/12/7/pubmed PY - 2008/2/6/medline PY - 2007/12/7/entrez SP - 95 EP - 101 JF - Gastroenterology JO - Gastroenterology VL - 134 IS - 1 N2 - BACKGROUND & AIMS: The temporal association between diabetes mellitus and pancreatic cancer is poorly understood. We compared temporal patterns in diabetes prevalence in pancreatic cancer and controls. METHODS: We reviewed the medical records of pancreatic cancer cases residing within 120 miles or less of Rochester, Minnesota, seen at the Mayo Clinic between January 15, 1981, and July 9, 2004, and approximately 2 matched controls/case residing locally. We abstracted all outpatient fasting blood glucose (FBG) levels for up to 60 months before index (ie, date of cancer diagnosis for cases) and grouped them into 12-month intervals; 736 cases and 1875 controls had 1 or more outpatient FBG levels in the medical record. Diabetes was defined as any FBG level of 126 mg/dL or greater or treatment for diabetes, and was defined as new onset when criteria for diabetes were first met 24 or fewer months before index, with at least 1 prior FBG level less than 126 mg/dL. RESULTS: A higher proportion of pancreatic cancer cases compared with controls met the criteria for diabetes at any time in the 60 months before index (40.2% vs 19.2%, P < .0001). The proportions were similar in the -60 to -48 (P = .76) and -48 to -36 (P = .06) month time periods; however, a greater proportion of cases than controls met criteria for diabetes in the -36 to -24 (P = .04), -24 to -12 (P < .001), and -12 to 0 (P < .001) month time periods. Diabetes was more often new onset in cases vs controls (52.3% vs 23.6%, P < .0001). CONCLUSIONS: Diabetes has a high (40%) prevalence in pancreatic cancer and frequently is new onset. Identification of a specific biomarker for pancreatic cancer-induced diabetes may allow screening for pancreatic cancer in new-onset diabetes. SN - 1528-0012 UR - https://www.unboundmedicine.com/medline/citation/18061176/Pancreatic_cancer_associated_diabetes_mellitus:_prevalence_and_temporal_association_with_diagnosis_of_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0016-5085(07)01920-8 DB - PRIME DP - Unbound Medicine ER -